178 related articles for article (PubMed ID: 27924072)
21. Expression of p53 in imprint smears of endometrial carcinoma.
Kosmas K; Stamoulas M; Marouga A; Kavantzas N; Patsouris E; Athanassiadou P
Diagn Cytopathol; 2014 May; 42(5):416-22. PubMed ID: 24167025
[TBL] [Abstract][Full Text] [Related]
22. Expression of immunoreactivity and genetic mutation in eosinophilic and ciliated metaplastic changes of endometrial glandular and stromal breakdown: cytodiagnostic implications.
Shimizu K; Norimatsu Y; Kobayashi TK; Sakurai M; Ogura S; Yoshizawa A; Miyamoto T; Miyake Y; Aratake Y; Sakaguchi T; Ohno E
Ann Diagn Pathol; 2009 Apr; 13(2):89-95. PubMed ID: 19302956
[TBL] [Abstract][Full Text] [Related]
23. TP53 overexpression in recurrent endometrial carcinoma.
Pijnenborg JM; van de Broek L; Dam de Veen GC; Roemen GM; de Haan J; van Engeland M; Voncken JW; Groothuis PG
Gynecol Oncol; 2006 Feb; 100(2):397-404. PubMed ID: 16271749
[TBL] [Abstract][Full Text] [Related]
24. Association of p53 and mdm2 in the development and progression of non-small cell lung cancer.
Javid J; Mir R; Julka PK; Ray PC; Saxena A
Tumour Biol; 2015 Jul; 36(7):5425-32. PubMed ID: 25672611
[TBL] [Abstract][Full Text] [Related]
25. [Correlation between Gli1 expression and clinicopathological significance in human pancreatic cancer].
Sheng WW; Dong M; Zhou JP; Liu QF; Li X; Dong Q
Zhonghua Wai Ke Za Zhi; 2013 Oct; 51(10):916-21. PubMed ID: 24433772
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of the infiltrative pattern invasion in endometrioid adenocarcinoma of the endometrium.
Suzuki C; Matsumoto T; Sonoue H; Arakawa A; Furugen Y; Kinoshita K
Pathol Int; 2003 Aug; 53(8):495-500. PubMed ID: 12895227
[TBL] [Abstract][Full Text] [Related]
27. Expression of p53 and mdm2 mRNA and protein in colorectal carcinomas.
Broll R; Stark A; Windhövel U; Best R; Strik MW; Schimmelpenning H; Schwandner O; Kujath P; Bruch HP; Duchrow M
Eur J Cancer; 1999 Jul; 35(7):1083-8. PubMed ID: 10533452
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
[TBL] [Abstract][Full Text] [Related]
29. CP‑31398 attenuates endometrial cancer cell invasion, metastasis and resistance to apoptosis by downregulating MDM2 expression.
Liu L; Yang L; Chang H; Chen YN; Zhang F; Feng S; Peng J; Ren CC; Zhang XA
Int J Oncol; 2019 Mar; 54(3):942-954. PubMed ID: 30628640
[TBL] [Abstract][Full Text] [Related]
30. Expression and significance of p53 and mdm2 in patients with leukoplakia cancer.
Cui JJ; Han XL; Wang WM
Asian Pac J Trop Med; 2013 Oct; 6(10):831-4. PubMed ID: 23870475
[TBL] [Abstract][Full Text] [Related]
31. P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome.
Jeczen R; Skomra D; Cybulski M; Schneider-Stock R; Szewczuk W; Roessner A; Rechberger T; Semczuk A
Clin Exp Metastasis; 2007; 24(7):503-11. PubMed ID: 17671841
[TBL] [Abstract][Full Text] [Related]
32. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C
Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716
[TBL] [Abstract][Full Text] [Related]
33. The pattern of p14ARF expression in primary and metastatic human endometrial carcinomas: correlation with clinicopathological features and TP53 pathway alterations.
Olcha P; Cybulski M; Skomra D; Obrzut B; Ignatov A; Jóźwik M; Schneider-Stock R; Semczuk A
Int J Gynecol Cancer; 2010 Aug; 20(6):993-9. PubMed ID: 20683407
[TBL] [Abstract][Full Text] [Related]
34. mdm2 mRNA level is a prognostic factor in soft tissue sarcoma.
Taubert H; Koehler T; Meye A; Bartel F; Lautenschläger C; Borchert S; Bache M; Schmidt H; Würl P
Mol Med; 2000 Jan; 6(1):50-9. PubMed ID: 10803408
[TBL] [Abstract][Full Text] [Related]
35. [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance].
Hu WF; Liu MQ; Zhao Q
Ai Zheng; 2004 Sep; 23(9):1021-5. PubMed ID: 15363194
[TBL] [Abstract][Full Text] [Related]
36. Expression of p53 in endometrial polyps with special reference to the p53 signature.
Sho T; Hachisuga T; Kawagoe T; Urabe R; Kurita T; Kagami S; Shimajiri S; Fujino Y
Histol Histopathol; 2016 Jul; 31(7):751-8. PubMed ID: 26727623
[TBL] [Abstract][Full Text] [Related]
37. Tumor necrosis factor-alpha mRNA and protein in endometrial tumors: analysis by in situ hybridization and immunocytochemistry.
Garcia FU; Chen HL; Yang Y; Pace JL; Hu XL; Hunt JS
Hum Pathol; 1994 Dec; 25(12):1324-31. PubMed ID: 8001927
[TBL] [Abstract][Full Text] [Related]
38. Direct sequencing of the p53 gene shows absence of mutations in endometrioid endometrial adenocarcinomas expressing p53 protein.
Stewart RL; Royds JA; Burton JL; Heatley MK; Wells M
Histopathology; 1998 Nov; 33(5):440-5. PubMed ID: 9839168
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of p53, bcl-2, vimentin, and S100 protein-positive Langerhans cells in endometrial carcinoma.
Coppola D; Fu L; Nicosia SV; Kounelis S; Jones M
Hum Pathol; 1998 May; 29(5):455-62. PubMed ID: 9596268
[TBL] [Abstract][Full Text] [Related]
40. L-type amino acid transporter 1 expression increases in well-differentiated but decreases in poorly differentiated endometrial endometrioid adenocarcinoma and shows an inverse correlation with p53 expression.
Watanabe J; Yokoyama Y; Futagami M; Mizunuma H; Yoshioka H; Washiya K; Hana K; Endou H; Okayasu I
Int J Gynecol Cancer; 2014 May; 24(4):659-63. PubMed ID: 24694899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
